Antibiotic Resistance Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The prevalence of drug-resistant infections is expected to propel the growth of the antibiotic-resistance market going forward. Drug-resistant infections are diseases caused by resistant bacteria, resulting in an infection that is far more difficult or impossible to cure. Antimicrobial resistance drugs help treat various drug-resistant infections with improved antibiotic treatment outcomes concerning both target and nontarget pathogens, dependent on the details of resistance mechanisms and microbiome community interaction structure. For instance, in November 2022, according to the European Centre for Disease Prevention and Control, a Sweden-based European Union agency for public health, around 35 000 persons in the EU/EEA die each year from antimicrobial-resistant diseases. Moreover, Klebsiella pneumoniae infections increased by 20% in 2021, and the number of Candida auris reported cases virtually doubled between 2020 and 2021. Therefore, the prevalence of drug resistance infection is driving the antibiotic resistance market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12131&type=smp

The antibiotic resistance market covered in this report is segmented –

1) By Drug Class: Beta Lactum Antibiotic, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, Oxazolidinones, Other Drug Classes

2) By Pathogen: Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus Faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, Other pathogens

3) By Disease Type: Urinary tract infection, Intra-abdominal infection, Blood stream infections, Clostridium difficile infections, Other Disease Types

4) By Mechanism of Action: Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Other Mechanism Of Actions

5) By End Users: Hospitals, Homecare, Specialty clinics, Other End-users

Product innovations are the key trend gaining popularity in the antibiotic resistance market. Major companies operating in the antibiotic resistance market are focused on developing innovative products to strengthen their position in the market. For instance, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical company, introduced Zidavi, a novel antibiotic for multi-drug resistant (MDR) infections, to ensure availability, affordability, and accessibility while saving the lives of critically ill patients. Zidavi is a unique combination of ceftazidime and avibactam that can treat infections caused by multi-drug resistant (MDR) gram-negative pathogens. It is available for infusion in sterile powdered concentrate for reconstitution, comprising ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam in each single-dose vial. Also, it offers an effective alternative to treat hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) caused by meropenem and colistin.

The antibiotic resistance market report table of contents includes: